AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests




Whatsapp News

AstraZeneca taps Roche, Qiagen for new blood-based cancer drug testsLONDON – AstraZeneca has signed Roche and Qiagen develop separate diagnostic tests, both using simple blood samples, identify who will benefit from its lung cancer .

Currently testing see if tumors contain genetic mutations make them suitable for drug treatment involves collecting a sample of tissue by needle biopsy or during surgery.

The new tests are based smart can detect small fragments of circulating tumor DNA in the plasma taken from ’ blood.[eap_ad_2]

The collaboration Qiagen involves developing such a test to accompany AstraZeneca’s established lung cancer pill Iressa, while the agreement Roche is for a companion diagnostic to go AstraZeneca’s experimental successor to Iressa called AZD9291.

AZD9291 targets a genetic mutation helps tumors evade existing treatments and AstraZeneca believes it could sell as much as $3 billion a year. The mutation, known as T790M, develops in about half of lung cancers become resistant to current epidermal growth factor receptor inhibitors like Iressa. (Reuters)[eap_ad_3]